Business Wire

LG Chem Is Targeting to Penetrate the Solar Panel Frame Market

19.10.2021 03:00:00 EEST | Business Wire | Press release

Share

LG Chem (KRX: 051910) has developed a plastic material that can replace the metal in solar panel frames for the first time in Korea and starts full-scale market penetration.

LG Chem announced that the Company has developed ‘LUPOY EU5201’, a PC/ASA flame retardant material that maintains the material shape even during temperature changes due to its low thermal expansion levels, using their proprietary technology and manufacturing method.

* PC/ASA: Engineering plastic with enhanced physical properties made by mixing ASA (Acrylonitrile Styrene Acrylate) resins with polycarbonate as a base

Solar panel frames are located at the edge of solar panels to protect and support the panel from external impact. Heat resistance and strong durability against corrosion are required as the materials are exposed outside for a long time, such as on exterior walls or the roof where there is direct sunlight. Solar panel frames account for about 10% of solar panels, and are mainly made of aluminum alloy.

The ‘LUPOY EU5201’, developed by LG Chem, is a high-performance engineering plastic material that supplements the mechanical properties of general plastics by adding glass fiber to polycarbonate compounds.

It has the same level of durability as existing aluminum, but is half the weight and has excellent price competitiveness. Also, it has excellent dimensional stability that maintains its shape even in temperature changes, so it is not easily deteriorated or deformed by the external environment. The chemical decomposition caused by ultraviolet rays exposure has been reduced, which has significantly improved the lifespan of the product compared to general plastics, and the color remains the same even after long-term exposure to ultraviolet rays.

If aluminum is replaced with LG Chem's new engineering plastic material, the weight of the solar panel is expected to decrease dramatically and material cost can also be reduced. This can bring increased convenience during transportation and installation.

LG Chem has PCR PC (Post-Consumer Recycled Polycarbonate) development technology that recycles plastics used by general consumers, so the Company can also produce eco-friendly low-carbon products using high-content PCR raw materials at the request of customers. The Company also plans to review ways to collect the solar panel frame that will be discarded in the future and reproduce them into PCR PC.

LG Chem has secured mass production capability during the first half of this year and started selling products in full-scale in the third quarter. Starting with the supply for solar panel frames, the Company plans to expand the application of materials to interior and exterior materials of automobiles in the future.

Steven Kim, Leader of the Engineering Materials Division at LG Chem, stated, “Solar panel frames made of plastic have many advantages that differentiate them from existing frames, such as ease of installation, and therefore have great market potential. Based on the world's best compounding technology, LG Chem plans to lead the rapidly growing solar material market through continuous R&D and investment into mass production capabilities.”

LG Chem declared ‘carbon-neutral growth by 2050’ last year, the first company to do so in the domestic petrochemical industry, and is promoting RE100, which produces products using renewable energy at all workplaces around the world. LG Chem plans to accelerate carbon-neutral growth through the transition to renewable energy and contribute to the development of renewable energy industry such as solar power through the development of LUPOY EU5201 product.

About LG Chem

LG Chem, Ltd. is Korea’s largest diversified chemical company which operates three main business units: Petrochemicals, Advanced Materials, Life Sciences. The chemical business manufactures a wide range of products, from petrochemical goods to high-value added plastics. It also extends its chemical expertise into high-tech areas such as electronic & battery materials and drugs & vaccines. Throughout multiple production facilities and an extensive distribution network, LG Chem strives to become a leading global company. For more information, please visit the LG Chem website at www.lgchem.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

LG Chem, Ltd.
Sangkyu Choi, Manager
+82-2-3773-7869
choisg@lgchem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 09:00:00 EET | Press release

Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s Radio City Music Hall and Intuit Dome in California. “People are seeking richer and more immersive e

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 08:00:00 EET | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as

vVARDIS Announces Pricing of Initial Public Offering13.11.2026 07:02:00 EET | Press release

vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file

Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release

The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release

VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye